Grants Awarded



Click on any project title for a more detailed description of the project. For more information about any of these awards (e.g., PI contact information or associated publications), please use the corresponding project number to search for information at the NIH Reporter website. Consistent with NIH policy, abstracts are not available for projects receiving their first award within the past year, so descriptions provided below are from the NCI program director.

New awards will be posted as they are issued.

Year Award Type Project # RFA # PI/Project Leader Institution Title Statussort ascending
2019 R33 RFA-CA-18-003 BREUNIG, JOSHUA JOHN CEDARS-SINAI MEDICAL CENTER GESTALT Barcoding and Single-cell Transcriptomics of Tumor Cell Evolution in Personalized Tumor Models Active
2022 R21 CA21-005 TANG, SINDY KAM-YAN STANFORD UNIVERSITY A micro-dissection platform for generating uniform-sized patient-derived tumor organoids (PDOs) for personalized cancer therapy Active
2020 R21 RFA-CA-19-019 TEWARI, MUNEESH UNIVERSITY OF MICHIGAN AT ANN ARBOR Highly Specific, Amplification-free, Single-molecule Counting Of Rare Methylated Dna Cancer Biomarkers Active
2019 R33 RFA-CA-18-003 VAN DAM, ROBERT MICHAEL UNIVERSITY OF CALIFORNIA LOS ANGELES Optimization and validation of integrated microscale technologies for low-cost; automated production of PET molecular imaging tracers for cancer research Active
2022 R21 CA21-003 KNOWLES, DAVID ARTHUR NEW YORK GENOME CENTER A CRISPR/Cas13 approach for identifying individual transcript isoform function in cancer Active
2020 R33 RFA-CA-19-020 WANG, SIYUAN YALE UNIVERSITY Multiplexed Imaging Of Chromatin Folding And Rna Profiles In Cancer Active
2019 R21 RFA-CA-18-004 SINGAMANENI, SRIKANTH WASHINGTON UNIVERSITY METAL-ORGANIC FRAMEWORK AS PROTECTIVE COATING FOR CANCER BIOSPECIMEN PRESERVATION Active
2022 R21 CA21-003 SOPER, STEVEN ALLAN UNIVERSITY OF KANSAS LAWRENCE Molecular Sub-typing Breast Cancer Patients using a Liquid Biopsy Active
2018 R21 RFA-CA-17-010 ABBOTT, KAREN L UNIV OF ARKANSAS FOR MED SCIS Novel platform linking cancer-specific glycosylation with cell signaling outcomes Active
2020 R43 PAR-18-303 WARREN, CHRISTOPHER L PROTEOVISTA, LLC Development Of The High Throughput Apt-snap Platform For Rapid Identification Ofnuclease-resistant Rna Aptamers Against P53 Missense Mutations Active
2019 R21 RFA-CA-18-004 ANDRES-MARTIN, LAURA NEW YORK STEM CELL FOUNDATION Establishing efficient technologies for ovarian cancer organoid derivation from fresh tumor resections Active
2022 R33 CA21-004 PAN, TAO UNIVERSITY OF CHICAGO Transfer RNA sequencing and application to cancer research and clinics Active
2018 R21 RFA-CA-17-010 BRENT, ROGER FRED HUTCHINSON CANCER RESEARCH CENTER Precision controllers of mammalian gene expression Active
2020 R33 RFA-CA-19-020 WEI, CHIA-LIN JACKSON LABORATORY Advancing Ultra Long-read Sequencing And Chromatin Interaction Analyses For Chromosomal And Extrachromosomal Structural Variation Characterization In Cancer Active
2019 R33 RFA-CA-18-005 LEI, YUGUO UNIVERSITY OF NEBRASKA LINCOLN A Single Conical Tube Device for Precision CAR-T Cells Manufacturing Active
2022 R33 CA21-004 LEE, ABRAHAM P UNIVERSITY OF CALIFORNIA-IRVINE Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy Active
2020 R44 PAR-18-303 WINTERS, IAN PAUL D2G ONCOLOGY, INC. Relating Drugs To Genotypes To Transform Precision Cancer Therapeutics With Tuba-seq - A Novel, Highly Scalable And Quantitative Preclinical Experimental Oncology Platform Active
2020 R21 RFA-CA-19-019 HUR, SOOJUNG CLAIRE JOHNS HOPKINS UNIVERSITY Development of a microfluidic primary cell editing platform (pCEP) for personal gene therapy Active
2022 R21 CA21-003 SNYDER, JOSHUA CLAIR DUKE UNIVERSITY Mouse Paint: A massively combinatorial approach for illuminating tumor heterogeneity in True Color Active
2020 R33 RFA-CA-19-020 HALL, ADAM ROGER WAKE FOREST UNIVERSITY HEALTH SCIENCES Detecting diverse nucleic acid biomarkers of cancer with solid-state nanopores Active
2020 R21 RFA-CA-19-019 REVZIN, ALEXANDER MAYO CLINIC ROCHESTER A microfluidic cell culture platform for personalizing pancreatic cancer therapies Active

Pages